These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
314 related articles for article (PubMed ID: 33541851)
1. Clinical Approach to Mast Cell Activation Syndrome: A Practical Overview. Matito A; Escribese MM; Longo N; Mayorga C; Luengo-Sánchez O; Pérez-Gordo M; Matheu V; Labrador-Horrillo M; Pascal M; Seoane-Reula ME; J Investig Allergol Clin Immunol; 2021 Dec; 31(6):461-470. PubMed ID: 33541851 [TBL] [Abstract][Full Text] [Related]
2. Low Prevalence of Idiopathic Mast Cell Activation Syndrome Among 703 Patients With Suspected Mast Cell Disorders. Zaghmout T; Maclachlan L; Bedi N; Gülen T J Allergy Clin Immunol Pract; 2024 Mar; 12(3):753-761. PubMed ID: 38056692 [TBL] [Abstract][Full Text] [Related]
3. Using the Right Criteria for MCAS. Gulen T Curr Allergy Asthma Rep; 2024 Feb; 24(2):39-51. PubMed ID: 38243020 [TBL] [Abstract][Full Text] [Related]
4. [Tryptase: A practical guide for the physician]. Lobbes H; Reynaud Q; Mainbourg S; Lega JC; Durieu I; Durupt S Rev Med Interne; 2020 Nov; 41(11):748-755. PubMed ID: 32712042 [TBL] [Abstract][Full Text] [Related]
5. Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review. Gülen T; Akin C; Bonadonna P; Siebenhaar F; Broesby-Olsen S; Brockow K; Niedoszytko M; Nedoszytko B; Oude Elberink HNG; Butterfield JH; Sperr WR; Alvarez-Twose I; Horny HP; Sotlar K; Schwaab J; Jawhar M; Zanotti R; Nilsson G; Lyons JJ; Carter MC; George TI; Hermine O; Gotlib J; Orfao A; Triggiani M; Reiter A; Hartmann K; Castells M; Arock M; Schwartz LB; Metcalfe DD; Valent P J Allergy Clin Immunol Pract; 2021 Nov; 9(11):3918-3928. PubMed ID: 34166845 [TBL] [Abstract][Full Text] [Related]
6. Global Classification of Mast Cell Activation Disorders: An ICD-10-CM-Adjusted Proposal of the ECNM-AIM Consortium. Valent P; Hartmann K; Bonadonna P; Gülen T; Brockow K; Alvarez-Twose I; Hermine O; Niedoszytko M; Carter MC; Hoermann G; Butterfield JH; Lyons JJ; Sperr WR; Greiner G; Sotlar K; Kluin-Nelemans HC; Schwaab J; Lange M; George TI; Siebenhaar F; Broesby-Olsen S; Jawhar M; Nedoszytko B; Castells M; Orfao A; Gotlib J; Reiter A; Horny HP; Triggiani M; Arock M; Metcalfe DD; Akin C J Allergy Clin Immunol Pract; 2022 Aug; 10(8):1941-1950. PubMed ID: 35623575 [TBL] [Abstract][Full Text] [Related]
7. Mast Cell Activation Syndromes: Collegium Internationale Allergologicum Update 2022. Valent P; Hartmann K; Bonadonna P; Niedoszytko M; Triggiani M; Arock M; Brockow K Int Arch Allergy Immunol; 2022; 183(7):693-705. PubMed ID: 35605594 [TBL] [Abstract][Full Text] [Related]
8. Idiopathic mast cell activation syndrome is more often suspected than diagnosed-A prospective real-life study. Buttgereit T; Gu S; Carneiro-Leão L; Gutsche A; Maurer M; Siebenhaar F Allergy; 2022 Sep; 77(9):2794-2802. PubMed ID: 35364617 [TBL] [Abstract][Full Text] [Related]
9. Mast cell activation syndromes presenting as anaphylaxis. Akin C Immunol Allergy Clin North Am; 2015 May; 35(2):277-85. PubMed ID: 25841551 [TBL] [Abstract][Full Text] [Related]
10. Hymenoptera Allergy and Mast Cell Activation Syndromes. Bonadonna P; Bonifacio M; Lombardo C; Zanotti R Curr Allergy Asthma Rep; 2016 Jan; 16(1):5. PubMed ID: 26714690 [TBL] [Abstract][Full Text] [Related]
11. Clinical impact of the TPSAB1 genotype in mast cell diseases: A REMA study in a cohort of 959 individuals. González-de-Olano D; Navarro-Navarro P; Muñoz-González JI; Sánchez-Muñoz L; Henriques A; de-Andrés-Martín A; Peralta-Arjonilla D; Mayado A; Jara-Acevedo M; García-Montero AC; Orfao A; Álvarez-Twose I Allergy; 2024 Mar; 79(3):711-723. PubMed ID: 37818990 [TBL] [Abstract][Full Text] [Related]
12. Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11β-prostaglandin2α. Ravi A; Butterfield J; Weiler CR J Allergy Clin Immunol Pract; 2014; 2(6):775-8. PubMed ID: 25439370 [TBL] [Abstract][Full Text] [Related]
13. Expanding spectrum of mast cell activation disorders: monoclonal and idiopathic mast cell activation syndromes. Picard M; Giavina-Bianchi P; Mezzano V; Castells M Clin Ther; 2013 May; 35(5):548-62. PubMed ID: 23642289 [TBL] [Abstract][Full Text] [Related]
14. Pathogenic and diagnostic relevance of KIT in primary mast cell activation disorders. Muñoz-González JI; García-Montero AC; Orfao A; Álvarez-Twose I Ann Allergy Asthma Immunol; 2021 Oct; 127(4):427-434. PubMed ID: 34298172 [TBL] [Abstract][Full Text] [Related]
15. Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation Syndrome. Valent P; Bonadonna P; Hartmann K; Broesby-Olsen S; Brockow K; Butterfield JH; Triggiani M; Lyons JJ; Oude Elberink JNG; Arock M; Metcalfe DD; Akin C Int Arch Allergy Immunol; 2019; 180(1):44-51. PubMed ID: 31256161 [TBL] [Abstract][Full Text] [Related]
16. Doctor, I Think I Am Suffering from MCAS: Differential Diagnosis and Separating Facts from Fiction. Valent P; Akin C J Allergy Clin Immunol Pract; 2019 Apr; 7(4):1109-1114. PubMed ID: 30961836 [TBL] [Abstract][Full Text] [Related]
17. Diagnosis, Classification and Management of Mast Cell Activation Syndromes (MCAS) in the Era of Personalized Medicine. Valent P; Akin C; Nedoszytko B; Bonadonna P; Hartmann K; Niedoszytko M; Brockow K; Siebenhaar F; Triggiani M; Arock M; Romantowski J; Górska A; Schwartz LB; Metcalfe DD Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33261124 [TBL] [Abstract][Full Text] [Related]
19. A Challenge for Allergologist: Application of Allergy Diagnostic Methods in Mast Cell Disorders. Romantowski J; Górska A; Niedoszytko M; Gulen T; Gruchała-Niedoszytko M; Nedoszytko B; Lange M; Brockow K; Arock M; Akin C; Valent P Int J Mol Sci; 2021 Feb; 22(3):. PubMed ID: 33535634 [TBL] [Abstract][Full Text] [Related]